EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Trial

David R Jayne iD, Jürgen Steffgen, Juanita Romero-Diaz, Ingeborg Bajema, Dimitrios T Boumpas, Kajohnsak Noppakun, Hirofumi Amano, Harold Michael Gomez, Bancha Satirapoj, Yingyos Avihingsanon, Ratana Chawanasuntorapoj, Magdalena Madero und 7 weitere

Arthritis & Rheumatology · 2023

DOI: 10.1002/art.42557 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von David R Jayne und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Lupus Nephritis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim, NIHR Cambridge Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To characterize its dose‐response relationship, BI 655064 (an anti‐CD40 monoclonal antibody) was tested as an add‐on to mycophenolate and glucocorticoids in patients with active lupus nephritis (LN).

Methods

A total of 121 patients were randomized (2:1:1:2) to receive placebo or BI 655064 120, 180, or 240 mg and received a weekly loading dose for 3 weeks followed by dosing every 2 weeks for the 120 and 180 mg groups, and 120 mg weekly for the 240 mg group. The primary endpoint was complete renal response (CRR) at week 52. Secondary endpoints included CRR at week 26.

Results

A dose‐response relationship with CRR at week 52 was not shown (BI 655064 120 mg, 38.3%; 180 mg, 45.0%; 240 mg, 44.6%; placebo, 48.3%). At week 26, 28.6% (120 mg), 50.0% (180 mg), 35.0% (240 mg), and 37.5% (placebo) achieved CRR. The unexpected high placebo response prompted a post hoc analysis evaluating confirmed CRR (cCRR, at weeks 46 and 52). cCRR was achieved in 22.5% (120 mg), 44.3% (180 mg), 38.2% (240 mg), and 29.1% (placebo) of patients. Most patients reported ≥1 adverse event (BI 655064, 85.7–95.0%; placebo, 97.5%), most frequently infections and infestations (BI 655064 61.9–75.0%; placebo 60%). Compared with other groups, higher rates of serious (20% vs. 7.5–10%) and severe infections (10% vs. 4.8–5.0%) were reported with 240 mg BI 655064.

Conclusion

The trial failed to demonstrate a dose‐response relationship for the primary CRR endpoint. Post hoc analyses suggest a potential benefit of BI 655064 180 mg in patients with active LN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisHumansAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsBiomarkersDouble-Blind MethodTreatment Outcome

Substanzen

BI 655064Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Medicine, University of Cambridge, Cambridge, UK.
  • Boehringer Ingelheim International GmbH, Biberach, Germany.
  • Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubiran", Mexico City, Mexico.
  • Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, the Netherlands.
  • Department of Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

ORCID-Profile: David R Jayne, Richard Furie

Förderung

  • Boehringer Ingelheim
  • NIHR Cambridge Biomedical Research Centre

Zitieren

APA

Jayne, D. R., Steffgen, J., Romero-Diaz, J., Bajema, I., Boumpas, D. T., Noppakun, K., Amano, H., Gomez, H. M., Satirapoj, B., Avihingsanon, Y., Chawanasuntorapoj, R., Madero, M., Naumnik, B., Recto, R., Fagan, N., Revollo, I., Wu, J., Visvanathan, S., & Furie, R. (2023). Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.42557

Vancouver

Jayne DR, Steffgen J, Romero-Diaz J, Bajema I, Boumpas DT, Noppakun K, et al. Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Trial. Arthritis & Rheumatology. 2023. doi:10.1002/art.42557

BibTeX
@article{Jayne2023,
  author = {Jayne, David R and Steffgen, Jürgen and Romero-Diaz, Juanita and Bajema, Ingeborg and Boumpas, Dimitrios T and Noppakun, Kajohnsak and Amano, Hirofumi and Gomez, Harold Michael and Satirapoj, Bancha and Avihingsanon, Yingyos and Chawanasuntorapoj, Ratana and Madero, Magdalena and Naumnik, Beata and Recto, Rhona and Fagan, Nora and Revollo, Ivette and Wu, Jing and Visvanathan, Sudha and Furie, Richard},
  title = {Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Trial},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  doi = {10.1002/art.42557}
}
Kostenlos starten →